Navigation Links
Defensins Ward Off HIV In Two Ways

The body attempts to protect itself from HIV infection via the innate immune system. Defensins are proteins found in cells, which have been shown to have anti-HIV activity. However, the mechanism by which the defensins control HIV infection has not been known. Appearing online on February 17 in advance of publication in the March 1 print edition of the Journal of Clinical Investigation, Theresa Chang and colleagues from Mount Sinai School of Medicine analyze how alpha-defensin-1, in particular, inhibits HIV infection in CD4+ T cells. CD4 + T cells are white blood cells that have molecules called CD4 on their exterior. They help orchestrate the body's response to viruses and therefore play important roles in the immune system.

The researchers show that alpha-defensin-1 fights HIV in two different ways. Without serum (the watery portion of blood that remains when blood cells are removed) and under conditions where viral burden is low, alpha-defensin-1 directly inactivates HIV virus. When serum is present, alpha-defensin-1 acts on vulnerable cells to block HIV infection at the stage when the virus is taken up by the cell and begins replicating itself and integrating into the host. The authors also show that the way alpha-defensin-1 blocks HIV infection in cells is by inhibiting a CD4+ cell-signaling molecule called PKC.

The finding that alpha-defensin-1 acts on both the virus and the cell offers insights into the function of alpha-defensin-1 in innate immunity against HIV. In addition, this study provides a basis to develop defensin-like drugs for prevention of HIV and for therapeutic use in patients who are already infected.


'"/>

Source:JCI


Page: 1

Related biology news :

1. Defensins neutralize anthrax toxin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
(Date:6/22/2016)... 2016   StockNewsNow.com , The Official MicroCap News ... Nader Pourhassan , President & CEO of CytoDyn ... clinical development and potential commercialization of humanized monoclonal antibodies ... to the company,s website (see here: www.CytoDyn.com ). ... th , 2016, at the LD Micro Invitational in ...
(Date:6/22/2016)... June 22, 2016  Mesa Biotech Inc., a ... testing platform designed specifically for point-of-care (POC) infectious ... scientific advisory board (SAB). Approved by the executive ... is chartered to advise on the development and ... Led by Dr. Steve Young , this ...
Breaking Biology Technology: